drugset / Trial / NCT05879068
A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
NaSingle-groupOpen-labelTreatment
Summary
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with paclitaxel as second line treatment for SCLC.
Timeline
- Start
- 2022-05-27
- Primary completion
- 2025-04-30
- Completion
- 2026-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pumitamig | Protein / enzyme biologic | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |